Press Releases and Blog
Blog
ICYMI: JC Scott In RealClearHealth: Amid Rising Health Care Premiums, Misguided Legislation Would Raise Costs Even Higher
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association, discusses how recent proposals being considered by Congress targeting
ICYMI: Former U.S. Senator Pat Toomey: Before Targeting PBMs, Republicans Should Consider The Unintended Consequences
In case you missed it, Pat Toomey, former U.S. Senator from Pennsylvania, cautioned lawmakers against legislation targeting pharmacy benefit companies and policies that meddle with
New JAMA Article Affirms Misguided Policies Targeting Pharmacy Benefit Companies Would Weaken Negotiating Power Against Big Pharma, Undercut Savings
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a new
“Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
The so-called “delinking” policy made news last week with the introduction of H.R. 6283. Among several glaring problems — including a rejection of free market
ICYMI: Competitive Enterprise Institute Explains How Pharmacy Benefit Companies Lower Health Care Costs
In case you missed it, the Competitive Enterprise Institute (CEI) released a new video, “Pharmacy Benefit Managers and Healthcare Costs: Not a Policy Paper, Just
ICYMI: Joe Grogan: Congress Wants A Better Value. So Why Are They Eliminating Performance Based Payment?
In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former domestic policy adviser under the previous administration, asked
Press Releases
Big Pharma Backed “Delinking” Legislation Threatens to Significantly Increase Prescription Drug Costs in Commercial Market
Economic Analyses Shows “Delinking” Policy Hands Big Pharma a Financial Windfall totaling $32 Billion Annually (Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) issued the
PCMA Statement on Senate Finance Committee Vote
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s vote in the Senate Finance Committee to advance legislation impacting
PCMA Statement on CMS’ Proposal to Promote the Use of Biosimilars in Medicare Part D
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) supports the Centers for Medicare and Medicaid Services’ (CMS) proposal to promote the use of biosimilars
Senate Finance Committee Bill Will Cost Taxpayers and is a $10 Billion Giveaway to Big Pharma
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on legislation introduced by Senate Finance Committee members: The just-released Senate
National Bureau of Economic Research Working Paper: “Delinking” Proposals that Restrict PBM Incentives to Secure Rx Savings Will Increase Drug Prices and Provide $10B Giveaway for Big Pharma
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on a new research paper, “Ending Pay for PBM Performance: Consequences
PCMA Statement on Legislation Introduced in the House of Representatives
(Washington, D.C.) — PCMA issued the following statement on legislation introduced in the House of Representatives: Legislation introduced in U.S. House of Representatives targeting pharmacy
ICYMI: JC Scott In RealClearHealth: Amid Rising Health Care Premiums, Misguided Legislation Would Raise Costs Even Higher
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association, discusses how recent proposals being considered by Congress targeting
ICYMI: Former U.S. Senator Pat Toomey: Before Targeting PBMs, Republicans Should Consider The Unintended Consequences
In case you missed it, Pat Toomey, former U.S. Senator from Pennsylvania, cautioned lawmakers against legislation targeting pharmacy benefit companies and policies that meddle with
New JAMA Article Affirms Misguided Policies Targeting Pharmacy Benefit Companies Would Weaken Negotiating Power Against Big Pharma, Undercut Savings
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a new
“Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
The so-called “delinking” policy made news last week with the introduction of H.R. 6283. Among several glaring problems — including a rejection of free market
ICYMI: Competitive Enterprise Institute Explains How Pharmacy Benefit Companies Lower Health Care Costs
In case you missed it, the Competitive Enterprise Institute (CEI) released a new video, “Pharmacy Benefit Managers and Healthcare Costs: Not a Policy Paper, Just
ICYMI: Joe Grogan: Congress Wants A Better Value. So Why Are They Eliminating Performance Based Payment?
In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former domestic policy adviser under the previous administration, asked
ICYMI: New Survey Finds Overwhelming Majority of Employers Value a Wide Range of Pharmacy Benefit Company Contract Options
Approximately 9 in 10 Employers Find Pharmacy Benefit Companies Valuable When Designing their Pharmacy Benefits and Say Flexibility and Choice are Essential In case you
Employers Choose Spread Pricing for a Reason
Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing
Correcting the Record: Pharmacy Benefit Companies Support and Promote Generics and Biosimilars
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed
Experts Urge Lawmakers to Reject “Delinking” and Other Proposed Policies That Will Increase Prescription Drug Costs
In case you missed it, Ike Brannon, senior fellow at the Jack Kemp Foundation and former senior economist for the United States Treasury and U.S.